Results: TGF-β1 induced EMT in HPMC

was ameliorated by metformin. TGF-β1 significantly increased the ROS generation and NOX activity from 30 minutes, and mitochondrial ROS production from 6 hours. TGF-β1 increased the phosphorylation of smad2/3 and MAPK at 30 minutes and 3 hours, respectively, which was followed by nuclear Epigenetics Compound Library clinical trial translocalization of β-catenin and snail up-regulation. Metformin ameliorated ROS production, the activation of smad2/3 and MAPK, and snail expression. Oral administration of metformin also decreased peritoneal thickening and EMT with an increase in ratio of reduced to oxidized glutathione and the expression and activity of superoxide dismutase in peritoneal dialysate whereas it decreased the expression of nitrotyrosine in peritoneum and 8-hydroxy-2′-deoxyguanosine in dialysate in 8 weeks of peritoneal dialysis. Conclusions: AMP-activated protein kinase activator prevented the peritoneum from phenotype transition and fibrosis via an amelioration of oxidative stress. MORI YOSHITAKA1, KAKUTA TAKATOSHI1, FK506 MIYATA TOSHIO2, FUKAGAWA MASAFUMI1 1Department of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan; 2United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Japan Introduction: Peritoneal

dialysis (PD) is an excellent modality of renal replacement therapy. However, PD has occasionally to be discontinued in few years primarily due to peritoneal membrane dysfunction, eventually leading to the ultrafiltration failure. Pyridoxamine inhibits the formation of AGEs by entrapping GDPs. We are studying whether pyridoxamine could prevent

the progressive deterioration of peritoneal function in uremic patients on peritoneal dialysis. We demonstrated that intraperitoneally and orally administrated pyridoxamine can prevent the deterioration of peritoneal function in uremic rats. For translating this animal research into clinical benefit, we performed a single-dose administration oxyclozanide of oral pyridoxamine in PD patients. Method: Pyridoxamine 600 mg was administered orally to 6 continuous ambulatory peritoneal dialysis (CAPD) patients. 2.5% peritoneal dialysis solution (PDS) was replaced 4times, 6hours each. Blood and PDS were collected for blood concentration of pyridoxamine and total carbonyl level in PDS. Same patients underwent the same procedure without oral pyridoxamine on another day. Single-dose administration to 6 non-uremic healthy volunteers was performed to compare the pharmacokinetics of pyridoxamine with PD patients. Result: Compared with non-uremic subjects, pyridoxamine level in blood elevated (Cmax 6.28 ± 2.45 μg/ml vs. 3.70 ± 1.04 μg/ml, AUC 30.10 ± 11.4 μg*hr/ml vs. 10.90 ± 1.30 μg*hr/ml). However, pyridoxamine concentration decreased almost to the original level within 24hours.